Tank vapor sampling and analysis data package for tank 241-C-106 waste retrieval sluicing system process test phase II sampled 03/07/1999

Physical education is the component can unify the cultures, languages, and nations. One of the current issues in the physical activity can be shown in the adaptive student. The purpose of this study was to facilitate the deaf student to get correct information and motivation to attending and joining physical activity in their class. Multicolor Flag Game (MFG) was a Research and Development model. The physical fitness elements are running back and forth, zig zag running, and running past the obstacles. Total participants in the trial and test I was 8 students, 10 students in trial and test phase II, and total 15 students used in the final test. The results of trial and test in phase I showed two of three aspects were Very Good, but one aspect needs attention for the perfection of the results. Cognitive aspect showed 93%, affective aspect 94%, and psychomotor 83%. The result of trial and test phase II significantly different, cognitive aspect in the trial and test phase II was 96%, affective 94%, and psychomotor 87%. The percentage of final test in cognitive was 98%, affective 96%, and psychomotor 90%, and all aspects were in Very Good category. These Multicolor Flag Game makes the atmosphere being excited and help the deaf student attending and participating in physical education class without any reason. MFG can improve student learning outcomes in cognitive, affective, and psychomotor aspects. MFG also can be one of the solutions for the teacher to select the alternative game and may be used as a reference in teaching physical education.

Download Full-text

Tank Vapor Sampling and Analysis Data Package for Tank 241-Z-361 Sampled 09/22/1999 and 09/271999 During Sludge Core Removal

10.2172/798823 ◽

1999 ◽

Author(s):

R.S. VISWANATH

Keyword(s):

Analysis Data ◽

Vapor Sampling

Download Full-text

Waste retrieval sluicing system vapor sampling and analysis plan for evaluation of organic emissions, process test phase III.

10.2172/782330 ◽

1999 ◽

Author(s):

L.M. SASAKI

Keyword(s):

Test Phase ◽

Phase Iii ◽

Vapor Sampling ◽

Sampling And Analysis Plan

Download Full-text

Safety test No. S-6, launch pad abort sequential test Phase II: solid propellant fire

10.2172/4178630 ◽

1975 ◽

Author(s):

E.C. Snow

Keyword(s):

Phase Ii ◽

Solid Propellant ◽

Test Phase ◽

Sequential Test ◽

Safety Test

Download Full-text

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.9593 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. 9593-9593 ◽

Cited By ~ 2

Author(s):

David Planchard ◽

Benjamin Besse ◽

Harry Groen ◽

Sayed MS Hashemi ◽

Julien Mazieres ◽

...

Keyword(s):

Phase Ii ◽

Cox Regression ◽

Genomic Analysis ◽

Analysis Data ◽

Pi3k Pathway ◽

Genetic Alterations ◽

Primary Objective ◽

Braf V600e ◽

Primary Analysis ◽

Open Label

9593 Background: The phase II multicenter, open label study, which evaluated efficacy and safety of D+T in pretreated (cohort B) and treatment (tx)-naive (cohort C) pts with BRAF V600E mut metastatic NSCLC. The results of the primary analysis have been reported. Here, we present an updated survival and genomic analysis data for cohorts B and C. Methods: Tx-naïve (n=36) and pretreated (n=57) pts received D 150 mg twice daily + T 2 mg daily. Primary objective: ORR, secondary objectives: PFS, DOR, OS, safety, tolerability and PK of D+T. Tumor samples were centrally tested using a NGS cancer targeted panel (Oncomine Dx Target test, ThermoFisher Scientific). KM curves and Cox regression models were used to evaluate potential associations between baseline genomic landscape and pt efficacy endpoints. Results: As of June 22, 2019, median (m) follow-up was 16.3 mo in tx-naïve pts and 16.6 mo in pretreated pts. mOS was 17.3 mo (95% CI: 12.3, 40.2; 3 yr OS: 40%) and 18.2 mo (95% CI: 14.3, 28.6; 3 yr OS: 33%) with 14/36 and 11/57 pts alive in tx naïve and pretreated pts respectively. Detailed efficacy results are presented in table. 57/62 tumor samples retrieved from 93 pts were centrally confirmed to have BRAF V600E mut; 5 non-confirmed BRAF tumors (3 pts had PR) were positive for c-MET T1010I, KRAS G12V, ALK fusion and 2 JAK3 S493C with mPFS of 13.8 mo while OS was NE due to limited data points. Eleven pts (18%) had concomitant somatic mutations and/or genetic alterations in addition to BRAF V600E mut: 4 had alterations within PI3K pathway4 had concomitant mutations at IDH1 R132X, and 3 pts had additional mutations at BRAF G466V, KRAS G13C and a cMET exon 14 skipping, respectively. Pts whose tumors had concomitant genetic alterations, particularly in PI3K pathway, showed a trend towards decreased PFS and OS. Safety profile was similar to previous reported results. Conclusions: This update of BRF113928 study reported improved and durable OS rates with combination D+T in BRAF V600E mut NSCLC pts. Co-occurring genetic alterations might influence clinical outcomes of such pts. Further validation is ongoing to corroborate current genomic findings. Clinical trial information: NCT01336634 . [Table: see text]

Download Full-text